Connect with us

Statistics

Coronavirus 2020 Outbreak: Latest Updates

The United States now leads the world in cases of COVID-19. We’ll provide the latest updates on coronavirus cases, government response, impacts to our daily life, and more.

What is the latest news?

Trump Say Worst Coming, 100,000 to 200,000 Deaths Expected

March 31, 8:31 p.m.

President Donald Trump and his top health officials warned that the worst is yet to come for the COVID-19 pandemic and that the next two or three weeks would be difficult.EXPANDED COVERAGELatest News

COVID-19 Death Rate Drops, Still Deadly to Seniors

COVID-19 Testing Hits Second Wall: Lack of Supplies

What Coronavirus Precautions Do You Really Need?

Social Distancing May Need to Last Months: Study

Health Workers Get Creative With Protective Gear

Getting Non-Coronavirus Care a Complicated Effort

The Power of Handwashing to Prevent CoronavirusExpert Opinions

Coronavirus in Context: New series with WebMD Chief Medical Officer Dr. John Whyte

Emory Expert: Allergies vs. COVID, Social Distancing, Is Takeout Safe?

At a White House coronavirus briefing Tuesday, officials unveiled models used that led to the decision to extend the “Stop the Spread” effort another 30 days, through April 30.

Based on several models, an estimated 100,000 to 200,000 deaths are expected. “This is a projection,” said Deborah Brix, MD, the White House Coronavirus Task Force response coordinator. “We really hope we can do better than that.”

The models take mitigation efforts into account. “There’s no magic bullet,” Birx said. “It is communities that will do this.”

Without mitigation, if the country were to just ”ride it out,” the models project that the number of deaths could be 1.5 to 2.2 million and beyond.

“We are really convinced that mitigation is going to be doing the trick for us,” said Anthony Fauci, MD, director of the NIH’s National Institute on Allergy & Infectious Diseases. “The 15 days that we [have] had clearly have had an effect although it is tough to quantitate. It is no time to take your foot off the accelerator.”

Birx acknowledged that social distancing and self-isolation are difficult. “This is tough,” she said. “It’s inconvenient from a social standpoint and an economic to do this but this is going to be the answer to our problem.”

More than 785 deaths were reported in the U.S. Tuesday, the highest single day total of the epidemic. The U.S. has more than 188,000 cases of the disease and more than 3,700 deaths.

Also at the briefing, Vice President Mike Pence said that more than 1.1 million tests for COVID-19 have been done. We are “testing about 100,000 Americans a day.”

CNN’s Chris Cuomo Diagnosed With COVID-19

March 31, 3:37 p.m 

One of CNN’s top anchors, Chris Cuomo, has been diagnosed with the coronavirus but will continue to work from home, he announced on his Twitter feed Tuesday.

“I have been exposed to people in recent days who have subsequently tested positive and I had fever, chills, and shortness of breath,” he wrote. “I just hope I don’t give it to the kids and Christina. That would make me feel worse than this illness!”

Cuomo said he’ll self-quarantine in the basement of his home and continue to do his 9 p.m. weekday program, “Cuomo Prime Time,” from there.

He worked from home on Monday and interviewed his brother, New York Gov. Andrew Cuomo.

32 States Have Issued Stay-at-Home Orders

March 31, 11:28 a.m.

Arizona Gov. Doug Ducey and Virginia Gov. Ralph Northam issued statewide stay-at-home orders on Monday, becoming the latest governors to take such action because of the coronavirus pandemic.

“We are in a public health crisis, and we need everyone to take this seriously and act responsibly,” Northam said in his order. “Our message to Virginians is clear: Stay home.”

Thirty-two states are now under statewide stay-at-home orders, plus the District of Columbia, according to The New York Times. California was the first state to do so, on March 19.

These states don’t have statewide orders, but some cities and counties have imposed their own stay-at-home orders: Alabama, Georgia, Florida, Maine, Mississippi, Missouri, Oklahoma, Pennsylvania, South Carolina, Texas, Utah, and Wyoming.

No stay-at-home orders have been issued in Arkansas, Iowa, Nebraska, Nevada, North Dakota, and South Dakota, according to The Times.

Statewide orders have now been issued in:

Alaska, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Montana, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oregon, Rhode Island, Tennessee, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

FDA OKs Anti-Malaria Drugs for COVID-19

March 31, 10:51 a.m. 

The FDA gave doctors the go-ahead to try two anti-malaria drugs to treat people with COVID-19, the disease caused by the new coronavirus.

The drugs are called chloroquine phosphate and hydroxychloroquine sulfate. The Department of Health and Human Services (HHS) says drugmakers have donated 30 million doses of hydroxychloroquine sulfate and 1 million doses of chloroquine phosphate to the strategic national stockpile.

HHS says the government will start shipping the drugs to states that need them.

So far, there aren’t many studies about using the anti-malaria medications as a treatment for COVID-19. But HHS says there are anecdotal reports that the drugs are helpful.

Denise Hinton, chief scientist for the FDA, says based on the scientific evidence available, it’s “reasonable to believe that chloroquine phosphate and hydroxychloroquine sulfate may be effective for the treatment of COVID-19.”

Clinical trials are underway to see if the drugs can safely treat COVID-19. The FDA says it’s OK for hospitals to use them for people with COVID-19 if they aren’t able to join a clinical trial.

The FDA also put out a warning about the danger of using a version of chloroquine phosphate that is an ingredient in fish tank water. The FDA says one person in the U.S. died and another became seriously ill after using the fish-tank version in an effort to prevent COVID-19.

Trump Details Machine that Decontaminates Respirator Masks

March 30, 7:02 p.m. 

The FDA has approved machinery that disinfects N95 respirator masks, meaning the masks could be reused by health care workers, President Donald Trump said Monday at a White House news briefing.

A shortage of the masks has been a major complaint as hospitals deal with a growing number of coronavirus patients. As of Monday afternoon, there are more than 152,000 cases in the United ­­States and over 2,700 deaths.

There are two disinfecting machines in Ohio and one in New York, with machines to be shipped soon to Seattle and Washington, D.C., Trump said.

The FDA approved the mask-cleaning equipment made by Ohio-based Battelle on Monday. Battelle said masks could be decontaminated up to 20 times “without degrading the mask’s performance.”

Also at the daily White House briefing:

  • Trump said 1 million Americans have been tested for the coronavirus. Health and Human Services Secretary Alex Azar said more than 100,000 people are being tested daily — more than any other country has tested. The data-tracking site called The COVID Tracking Project confirms that nearly 1 million tests have been conducted.
  • In response to a reporter’s question, Trump said he thinks any American who needs a ventilator will have access to one within a few weeks. That marks a shift from just last week, when he would not confirm the country’s supply of ventilators would be adequate.
  • Trump said he and his advisers have discussed a national stay-at-home order, similar to the ones issued in many states, but he said, “it’s pretty unlikely at this time.”
  • FDA Commissioner Stephen Hahn discussed the rapid-result coronavirus test approved last Friday. The advantage of the test is that patients can find out within 15 minutes if they have coronavirus, and get the answer in a doctor’s office or any other place they’re tested.

Johnson & Johnson to Test COVID-19 Vaccine Candidate

March 30, 5:46 p.m.

Johnson & Johnson said Monday that human clinical trials for a COVID-19 vaccine it has developed will start by September.

There is no approved vaccine for COVID-19 and no treatment for the disease. If the trial starts as planned, it will be the second one testing for a potential vaccine. In March, the National Institutes of Health started a phase 1 trial for a vaccine called mRNA-1273. It was developed by federal scientists and the biotechnology company Moderna Inc.,

Phase 1 trials test if a vaccine is safe. If it is, the potential vaccine then moves to broader testing to see how well it works and the side effects.

Johnson & Johnson says it is working with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services. The company and BARDA have pledged $1 billion for vaccine research, development and clinical testing.

The company said in a news release that its goal is to have the vaccine­ available for emergency use authorization by early 2021.

FDA OKs Ventilator Sharing

Updated March 30, 2:45 p.m. 

The FDA says hospitals may get creative if they get overwhelmed with COVID-19 patients who need lifesaving ventilators.

Agency officials on Friday issued an “Emergency Use Authorization” that lets doctors consider attaching the breathing machines to more than one person at a time. The FDA also says devices like anesthesia gas machines may be modified so they can be used as ventilators.

The New York Times reports that one New York City medical center — New York-Presbyterian — has already started to put two people on one ventilator. The hospital has developed guidelines that can help doctors set up ventilator sharing in other medical centers.

There hasn’t been much research on sharing ventilators. One small study, done in the aftermath of the 9/11 and Hurricane Katrina disasters, shows that it might be possible for four people to use a single ventilator for up to 12 hours. But that study used “simulated” patients, not real people.

Sharing ventilators is controversial among medical experts. Several medical groups, including the Society of Critical Care Medicine, issued a joint statement expressing concern about the procedure.

The groups warn that ventilator sharing is a complex process and might be risky. For example, a single patient who suddenly starts breathing on their own could cause the ventilator to reset the oxygen supply for everyone sharing that device.

How many people have been diagnosed with the virus, and how many have died?

According to Johns Hopkins University, there are more than 803,650 cases and 39,000 deaths worldwide. More than 170,000 people have also recovered. 

Italy, Spain and China have the most deaths. 

For the first time since the outbreak began in December, China — once the epicenter of what would become a global pandemic — reported no new domestic cases last week. The Chinese government is lifting the lockdown on Hubei Province and Wuhan, the capital, where the pandemic originated. There have been more than 82,000 cases in China and more than 3,200 deaths there. 

How many cases of COVID-19 are in the United States?

There are more than 162,000 cases in the U.S. of COVID-19 and almost 3,000 deaths, according to data complied by Johns Hopkins University and The COVID Tracking Project. See a map of cases and deaths by state here. 

New York, New Jersey and Washington are the states with the most deaths.

What travel restrictions are there?

The State Department has urged all U.S. citizens to avoid any international travel due to the global impact of the new coronavirus.

If you are currently overseas, the department wants you to come home, “unless [you] are prepared to remain abroad for an indefinite period,” according to a statement.

“Many countries are experiencing COVID-19 outbreaks and implementing travel restrictions and mandatory quarantines, closing borders and prohibiting non-citizens from entry with little advance notice,” the agency says.

In addition, the State Department says it will not issue any new passports except for people with a “qualified life-or-death emergency and who need a passport for immediate international travel within 72 hours.” The U.S. is banning all foreign travel to the United States from most of Europe for 30 days beginning midnight Friday, March 13.  American citizens are not included in the ban. 

The U.S. has also temporarily suspended nonessential travel to Mexico and Canada.

clock here to read more on crohnsdigest

Statistics

Covid vaccine tracker: How’s my country and the rest of the world is doing?

When it comes to the coronavirus vaccine there is one question most people are asking – when will I get it? A handful of countries have set very specific vaccination targets, but for the rest of the world, the picture is less clear.

Getting the world vaccinated against Covid-19 is a matter of life and death, involving complicated scientific processes, multinational corporations, government promises, and backroom deals. So figuring out when and how everyone in the world will get the vaccine is not easy.

Agathe Demarais is the director of global forecasting at the Economist Intelligence Unit, which has done some of the most comprehensive research on the topic. She has looked at the world’s production capacity, along with the healthcare facilities needed to get vaccines into people’s arms, the number of people a country has to contend with, and what they can afford.

  • Coronavirus cases, deaths, vaccinations by country
  • Will countries be left behind in the vaccine race?
  • The vaccines that work – and the others on the way

Many of the findings seem to fall along predictable lines of rich v poor. The UK and the US are both well supplied with vaccines right now because they could afford to invest a lot of money into vaccine development and put themselves at the front of the queue.

Rich countries that didn’t do that, like Canada or those in the EU bloc, are a little further behind. Canada was criticized at the end of last year for buying up five times the supply it needs to cover its population, but it seems it wasn’t positioned for priority delivery.

That’s partly because the country decided to invest in vaccines from European factories, afraid that the US under Donald Trump would issue export bans. It turned out to be a bad bet. European factories are struggling with supply and recently it has been the EU, not the US, that has been threatening export bans.

“As long as the European market doesn’t have enough vaccines, I think that big imports to Canada are going to remain off the cards,” says Ms. Demarais. Most low-income countries haven’t started vaccinating yet. But some countries in the middle are doing better than expected.

Global vaccine rollout

Enter a country or territory to find out the progress of the vaccine rollout

Type in 2 or more characters for results.

Serbia is eighth in the world in terms of the percentage of its population vaccinated, ahead of any country in the EU.

Its success is partly down to an efficient roll-out but it’s also benefitting from vaccine diplomacy – a battle between Russia and China for influence in eastern Europe. It’s one of the few places where the Russian vaccine Sputnik V and the Chinese vaccine SinoPharm are already available.

On paper, Serbians are given a choice of what vaccine they would prefer – Pfizer, Sputnik, or SinoPharm. In reality, most people end up being given SinoPharm.

And the influence China is exerting here is likely to be long-term. Countries giving a first and second dose of one of the Chinese vaccines are also likely to look to Beijing for booster doses if needed.

The United Arab Emirates is also relying heavily on the SinoPharm vaccine – it makes up 80% of the doses being administered there right now. And the UAE is building a SinoPharm production facility.

“China is coming with production facilities, trained workers, so it’s going to give long-term influence to China,” says Ms. Demarais. “And it will make it very, very tricky for recipient governments to say no to China for anything in the future.”

Being a global vaccine superpower, however, doesn’t mean your population will be vaccinated first. The EIU’s research predicts two of the world’s vaccine production powerhouses, China and India, may not be sufficiently vaccinated until the end of 2022. That’s because they have huge populations to contend with, as well as a shortage of health workers.

In India, the country’s success as a Covid vaccine producer is largely down to one man, Adar Poonawalla. He’s chief executive of the Serum Institute of India, the world’s largest vaccine producer.

Last year, his family started to think he has lost his mind when he began betting hundreds of millions of dollars of his own money on vaccines that he didn’t know would work.

In January, the first of those vaccines, developed by Oxford and AstraZeneca, was delivered to the Indian government. Now he’s producing 2.4 million doses a day. He’s one of two main suppliers to the Indian government – and is also supplying Brazil, Morocco, Bangladesh, and South Africa.

‘Magic sauce’

“I thought the pressure and all the madness would end now that we’ve made the product,” he says. “But the real challenge is trying to keep everybody happy.

“I thought there’d be so many other manufacturers who would be able to supply. But sadly, at the moment at least, in the first quarter, and perhaps even the second quarter of 2021, we’re not going to see a substantial increase in supply.”

He says production cannot be ramped up overnight. “It takes time,” Mr. Ponnawalla adds. “People think that the Serum Institute has got a magic sauce. Yes, we’re good at what we do but it’s not a magic wand.” He currently has an edge because he started building facilities in March last year, as well as stockpiling things like chemicals and glass vials in August.

For manufacturers starting production now, it will take months to produce vaccines. And the same applies to any boosters that might be needed to tackle new variants.

Mr. Ponnawalla says he is committed to supplying India and then Africa through a scheme called the Covax facility.

Coax, an initiative led by the WHO and other health organizations aims to get affordable vaccines to every country in the world. Countries that can’t afford vaccines will get them for free through a special fund. The rest will pay. But the theory is that they will get a better price by negotiating through the bloc than if they had done so on their own.

Coax is planning to start delivering vaccines this month. But the plan is being undermined by the fact many countries involved are also negotiating their deals on the side.

Mr. Poonawalla says almost every leader in Africa has been in touch with him to access vaccines independently. Last week, Uganda announced it had secured 18 million doses from the Serum Institute at $7 a jab – much more than the $4 being paid by Coax. The institute says it is in talks with Uganda but denies this deal was ever signed.

In total, Mr. Poonawalla’s firm is due to supply 200m doses of the AstraZeneca vaccine to Covax and has promised 900m more doses in the future.

The Africa Centres for Disease Control and Prevention has since advised against the rollout of the vaccine in countries where the South African strain is present. He says he is still committed to the scheme but admits it faces problems. It’s dealing with too many different vaccine producers, he says, each offering varying prices and timelines for delivery.

Ms. Demarais and the EIU are not overly optimistic about what Covax can achieve either. The timelines for delivery of vaccines are still not clear and even if things go according to plan, the scheme only aims to cover 20-27% of a country’s population this year. “It’s going to make a small marginal difference, but not a game-changer,” she says.

In her forecast, some countries may not get widespread coverage even by 2023. Some may never be fully covered. Vaccination may not be a priority for every country, especially one that has a young population and is not seeing huge numbers of people getting sick.

The problem with that scenario is as long as the virus can prosper somewhere it will be able to mutate and migrate. Vaccine-resistant variants will continue to evolve.

It’s not all bad news. Vaccines are being produced faster than ever but the scale of the task – inoculating 7.8 billion people around the world – is gigantic. And it’s never been attempted before.

Ms. Demarais believes governments should level with their people on what is possible. “It’s very difficult for a government to say, ‘No, we’re not going to achieve widespread immunization coverage before several years.’ Nobody wants to say that.”

Continue Reading

Statistics

Vaccines against Covid-19

Data from two separate studies published in the UK, one in England and another in Scotland, have shown vaccines against Covid-19 are effective in cutting disease transmission and hospitalizations from the first dose.
Analysis from Public Health England has shown the vaccine manufactured by Pfizer-BioNTech reduces the risk of catching infection by more than 70% after a first dose.
That risk is reduced by 85% after a second dose.
The public health body’s study of real-world data also showed vaccinated people who go on to become infected are far less likely to die or be hospitalized.
Hospitalization and death from Covid-19 are reduced by over 75% in those who have received a dose of the Pfizer-BioNTech vaccine, according to the analysis.
“This crucial report shows vaccines are working — it is extremely encouraging to see evidence that the Pfizer vaccine offers a high degree of protection against coronavirus,” Health Secretary Matt Hancock said.
Britain is one of the countries hardest-hit by the Covid-19 pandemic, with 120,757 deaths.
It was the first nation to begin mass vaccinations in December and more than 17 million people have now received at least a first vaccine dose, one-third of the UK’s adult population.
“We will see much more data over the coming weeks and months but we should be very encouraged by these initial findings,” said Dr. Mary Ramsay, Head of Immunisation at Public Health England.
At the same time, a study in Scotland has shown the Pfizer-BioNTech and Oxford-AstraZeneca vaccinations have led to a reduction in Covid-19 admissions to hospitals after a first dose.
The study, led by the University of Edinburgh, found that by the fourth week after receiving the initial dose the Pfizer vaccine reduced the risk of hospitalization from Covid by up to 85%.
The Oxford-AstraZeneca vaccine reduced the risk by 94%.
“These results are very encouraging and have given us great reasons to be optimistic for the future,” Professor Aziz Sheikh, who lead the research, said in a statement.
“We now have national evidence, across an entire country, that vaccination protects Covid-19 hospitalizations.
“Roll-out of the first vaccine dose now needs to be accelerated globally to help overcome this terrible disease,” he added.
The research compared the outcomes of those who had received their first jab with those who had not.
It found that vaccination was associated with an 81% reduction in hospitalization risk in the fourth week among those aged 80 years and over when the results for both vaccines were combined.
The project, which used patient data to track the pandemic and the vaccine roll-out in real-time, analyzed a dataset covering the entire Scottish population of 5.4 million between 8 December and 15 February.
Some 1.14 million vaccines were administered to 21% of the Scottish population during the period.
The Pfizer vaccine was received by 650,000 people in Scotland, while 490,000 had the Oxford-AstraZeneca vaccine.
It is the first research to describe the effect of vaccinations on preventing severe illness resulting in hospitalization across an entire country.
Previous results about vaccine efficacy have come from clinical trials.
The study team said the findings applied to other countries using the Pfizer and Oxford-AstraZeneca vaccines.
The data reported “is extremely promising,” said Arne Akbar, the president of the British Society for Immunology.
“Although there does seem to be some difference in effectiveness levels measured across age groups, the reduction in hospitalizations for the older age groups is still impressively high,” he said.
“We now need to understand how long-lasting this protection is for one dose of the vaccine.”

Continue Reading

Statistics

Taking Care of Your Mental Health Is a Key Piece of the puzzel to crohns disease

When you have Crohn’s disease or ulcerative colitis, it’s not just your physical health that’s affected. The frequent pain, unpredictability, and worrying that comes with inflammatory bowel disease can disrupt your emotional wellbeing, too.

And that stress, in turn, can make your IBD symptoms even worse.

“It’s pretty well understood that, while stress does not cause IBD, it contributes to flares, and it can contribute to the first expression of IBD,” says Stephen Lupe, PsyD, a clinical health psychologist who specializes in digestive diseases.

That’s why taking care of your emotional wellbeing is a critical part of managing your IBD.

“A lot of patients get stuck in this cycle of putting their life on hold while they try to cope with the disease, and that tends to increase depression, increase anxiety and increase stress,” he explains.

“But we want them to know that they can have a life and the disease at the same time. There are things that we can do to help their bodies cope with these conditions.”

Mental health and IBD go hand-in-hand

Studies have found that people who have IBD are more likely to develop anxiety and depression than people who don’t have it.

“Sometimes, people who are frequently in pain start to become predictive with the pain way before it ever happens, and they’ll stop doing things in anticipation of the pain,” Dr. Lupe notes. “Maybe they’ll stop eating, or they’ll stop going out, and their lives get narrower and narrower, which a lot of times can influence the development of anxiety or depression.”

Sleep problems are also common in people who have IBD, especially during a flare, he adds.

It’s important to be aware of these risks. If you’ve lost interest in doing things you used to love, or are struggling with the day-to-day challenges of living with a chronic gut disorder, speak up and let your doctor know what’s going on. He or she is there to help.

“A lot of gastroenterologists know psychologists that they can refer patients to,” Dr. Lupe says.

Can a health psychologist help you?

If you’re already frequenting your doctor’s office, making yet another medical appointment might not be at the top of your “things I want to do” list.

But seeking help to cope with the mental and emotional aspects of the disease can be an important step in improving your quality of life and managing symptoms. Research suggests that the gut and the brain are connected through the gut-brain axis and that stress may make symptoms worse.

“My job is to talk to patients about all of the things that come along with being diagnosed with a gut condition, whether that’s stress, anxiety or depression, or the lifestyle modifications that need to happen,” Dr. Lupe says.

“We also look at things like body image issues, the stress, and fear that can sometimes come along with having to use the bathroom frequently, and even things like talking to our partners about the sexual performance after being diagnosed.”

A psychologist may recommend one of these forms of therapy:

  • Cognitive-behavioral therapy, which focuses on changing thinking and behavioral patterns.
  • Acceptance and commitment therapy, where people learn to accept the challenges that come with their condition and focus on being present and mindful in their situation.
  • Hypnotherapy, which uses mind-body techniques to help people reach a relaxed state where they are more open to suggestions that may influence the quantity or intensity of symptoms.

Many people find additional support in the form of online or IRL support groups. “This can be very normalizing and validating to meet other people who have the same kinds of things going on in their life,” Dr. Lupe says.

But ongoing struggles with mood, stress, body image, sleep, anxiety, or coping with the day-to-day challenges of living with IBD should be addressed by a mental health professional.

“I think there’s a lot of stigmas, and a lot of patients have fear of talking about some of this other stuff that’s going on,” Dr. Lupe says. “People don’t always realize that there are things that we can do to help our bodies and minds cope so that we can have a life and keep moving forward. So make sure that you advocate for yourself and find a way to talk to someone.”

Continue Reading

Most Read